An angina drug called trimetazidine has been in the news lately connected to the 2022 Winter Olympics, but it's been on the radar of anti-doping authorities for years. Russian media reported that the ...

LOS ANGELES, March 27 (Reuters) - An angina drug made by CV Therapeutics Inc. failed to prove effective as a treatment for acute coronary syndrome, but favorable safety data could broaden its use, ...

Palo Alto, California Fears over QT prolongation are mounting for a range of already approved drugs, as well as for agents still in the pipeline. This past week, ranolazine, CV Therapeutics' new ...

New York, NY - Fifteen US state attorneys general have signed a joint federal lawsuit against two pharmaceutical companies for allegedly delaying the entry of a competing hypertension/angina drug into ...